,chunk_label,chunk_text,uuid
0,methods0," Monitoring		 Data monitoring	21a	Composition of data monitoring committee (data monitoring committee (DMC)); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a data monitoring committee (DMC) is not needed	-	 	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-	 Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	4–5	 Auditing	23	Frequency and procedures for auditing trial conduct, if any,",94272282-af3a-4db2-a432-5643c3ccfa5f
1,methods1," and whether the process will be independent from investigators and the sponsor	10	 Ethics and dissemination		 Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	3,14	 Protocol amendments	25	Plans for communicating important protocol modifications (e.g., changes to eligibility criteria, outcomes, analyses) to relevant parties (e.g., investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	4	 Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4	 	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-	 Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during,",eac4fcca-8a8d-4f17-b592-b3de58e52f23
2,methods2," and after the trial		 Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	14	 Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators		 Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation		 Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (e.g.",bd21e05e-72b7-46d9-b228-1972c792613a
3,methods3,", via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions		 	31b	Authorship eligibility guidelines and any intended use of professional writers	-	 	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-	 Appendices				 Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates		 Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable		 * It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated.",8d33f6ab-cb1b-4e6c-bb65-0fd34bbbca7b
4,methods4," The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.  Figure 1 Study flow chart including patients’ enrollment steps, baseline assessment measurements, random allocation to intervention and post-intervention measurements.; QoL: quality of life; NG: nutraceuticals group; CG: control group.  Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. =",9cb71cd3-939a-46db-95dc-75dd14be0e3f
